AcquisitionOther
KINETA, INC./DE acquired Kineta’s KVA12123 Immuno-Oncology Drug Program Kineta will receive a
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
KINETA, INC./DE -> Kineta’s KVA12123 Immuno-Oncology Drug Program Kineta will receive a · $5 million
The company’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial in patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27.
Open source record (SEC) ↗